MX2010006101A - Compuestos de triazol [4,5-d] pirimidina para tratamiento de aneurismas aorticas abdominales. - Google Patents

Compuestos de triazol [4,5-d] pirimidina para tratamiento de aneurismas aorticas abdominales.

Info

Publication number
MX2010006101A
MX2010006101A MX2010006101A MX2010006101A MX2010006101A MX 2010006101 A MX2010006101 A MX 2010006101A MX 2010006101 A MX2010006101 A MX 2010006101A MX 2010006101 A MX2010006101 A MX 2010006101A MX 2010006101 A MX2010006101 A MX 2010006101A
Authority
MX
Mexico
Prior art keywords
triazolo
treatment
abdominal aortic
aortic aneurysms
pyrimidine compounds
Prior art date
Application number
MX2010006101A
Other languages
English (en)
Spanish (es)
Inventor
Jean-Baptiste Michel
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2010006101A publication Critical patent/MX2010006101A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2010006101A 2007-12-03 2008-12-02 Compuestos de triazol [4,5-d] pirimidina para tratamiento de aneurismas aorticas abdominales. MX2010006101A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07301616 2007-12-03
PCT/SE2008/051386 WO2009072967A1 (en) 2007-12-03 2008-12-02 Triazolo [4,5-d] pyrimidine compounds for treatment of abdominal aortic aneurysms

Publications (1)

Publication Number Publication Date
MX2010006101A true MX2010006101A (es) 2010-10-04

Family

ID=40717966

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010006101A MX2010006101A (es) 2007-12-03 2008-12-02 Compuestos de triazol [4,5-d] pirimidina para tratamiento de aneurismas aorticas abdominales.

Country Status (24)

Country Link
US (2) US20100298350A1 (enExample)
EP (1) EP2229172B1 (enExample)
JP (1) JP5701060B2 (enExample)
KR (1) KR101563757B1 (enExample)
CN (2) CN101883565A (enExample)
AU (1) AU2008331984B2 (enExample)
BR (1) BRPI0819458A2 (enExample)
CA (1) CA2707488C (enExample)
CY (1) CY1115760T1 (enExample)
DK (1) DK2229172T3 (enExample)
EA (1) EA201000928A1 (enExample)
ES (1) ES2522317T3 (enExample)
HR (1) HRP20141081T1 (enExample)
IL (1) IL205613A (enExample)
MX (1) MX2010006101A (enExample)
MY (1) MY159656A (enExample)
NZ (1) NZ585513A (enExample)
PL (1) PL2229172T3 (enExample)
PT (1) PT2229172E (enExample)
RS (1) RS53635B1 (enExample)
SI (1) SI2229172T1 (enExample)
UA (1) UA100864C2 (enExample)
WO (1) WO2009072967A1 (enExample)
ZA (1) ZA201003599B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102653539B (zh) * 2011-03-01 2014-09-17 秦引林 一种抗血小板聚集化合物及其药物组合
CN102924457A (zh) * 2011-08-12 2013-02-13 上海恒瑞医药有限公司 三唑并嘧啶类衍生物、其制备方法及其用途
EP2750676B1 (en) 2011-08-30 2018-01-10 University of Utah Research Foundation Methods and compositions for treating nephrogenic diabetes insipidus

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997003084A1 (en) * 1995-07-11 1997-01-30 Astra Pharmaceuticals Ltd. New inhibitors of platelet aggregation
AR017014A1 (es) * 1997-07-22 2001-08-22 Astrazeneca Ab Compuestos de triazolo [4,5-d]pirimidina, composiciones farmaceuticas, uso de los mismos para preparar medicamentos y procesos para la preparacionde dichos compuestos
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
SE0101932D0 (sv) * 2001-05-31 2001-05-31 Astrazeneca Ab Pharmaceutical combinations
WO2009007675A2 (en) * 2007-07-11 2009-01-15 Cardoz Ab Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a p2 gamma 12 antagonist

Also Published As

Publication number Publication date
IL205613A0 (en) 2010-11-30
ES2522317T3 (es) 2014-11-14
PT2229172E (pt) 2014-11-03
SI2229172T1 (sl) 2014-12-31
WO2009072967A1 (en) 2009-06-11
EP2229172B1 (en) 2014-09-10
UA100864C2 (uk) 2013-02-11
HK1148195A1 (en) 2011-09-02
KR101563757B1 (ko) 2015-10-27
CA2707488A1 (en) 2009-06-11
ZA201003599B (en) 2012-10-31
NZ585513A (en) 2012-07-27
AU2008331984A1 (en) 2009-06-11
CN101883565A (zh) 2010-11-10
BRPI0819458A2 (pt) 2015-05-05
KR20100099175A (ko) 2010-09-10
HRP20141081T1 (hr) 2015-01-02
JP5701060B2 (ja) 2015-04-15
CY1115760T1 (el) 2017-01-25
PL2229172T3 (pl) 2015-01-30
DK2229172T3 (da) 2014-11-10
US20150272955A1 (en) 2015-10-01
EP2229172A4 (en) 2012-12-26
AU2008331984B2 (en) 2012-08-16
CA2707488C (en) 2015-07-28
EP2229172A1 (en) 2010-09-22
CN103919781A (zh) 2014-07-16
MY159656A (en) 2017-01-13
RS53635B1 (sr) 2015-04-30
IL205613A (en) 2015-04-30
EA201000928A1 (ru) 2010-12-30
JP2011505417A (ja) 2011-02-24
US20100298350A1 (en) 2010-11-25

Similar Documents

Publication Publication Date Title
TNSN07323A1 (en) Imidazo (1, 2-a) pyridine compounds as vegf-r2 inhibitors
WO2007059257A3 (en) N4-phenyl-quinaz0line-4 -amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
GB2453058A (en) Kinase antagonists
MX2011006334A (es) Polimorfos de (s)-3-amino-metil-7-(3-hidroxi-propoxi)-3h-benzo-[c] [1,2]-oxaborol-1-ol.
MY157724A (en) IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS
TW200626068A (en) Active compounds for seed treatment
WO2007100610A3 (en) Pyridine, pyrimidine and pyrazine derivatives as cxcr3 receptor modulators
CR10249A (es) Compuestos de amino- pirimidina 2,6-sistituidos -4-monosustituidos como antagonistas del receptor de prostaglandina d2
SG178591A1 (en) Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer
NL2000375A1 (nl) Pyrimidinederivaten voor de behandeling van abnormale celgroei.
MY169738A (en) Fused bicyclic pyrimidines
UA95247C2 (ru) Пиримидиновые соединения как модуляторы рецептора серотонина
WO2008060693A3 (en) Tetracyclic imidazole analogs
WO2009059143A3 (en) Use of toll-like receptor 4 antagonists for the treatment or prevention of osteoarthritic conditions
MX2008011576A (es) Compuestos de imidazo[2,1-b]tiazol sustituidos y su uso para la produccion de farmacos.
AP2241A (en) Pyrimidine derivatives for the treatment of abnormal cell growth.
CL2008001837A1 (es) Uso de compuestos derivados de cinolin-3-carboxamida en el tratamiento de la esquizofrenia.
UA100864C2 (uk) Спосіб лікування або запобігання аневризмі черевної аорти
DK1742950T3 (da) Pyrazolo-[4,3-D]-pyrimidiner
MY143089A (en) Pyrido[2,3-d] pyrimidine derivatives, preparation thereof, therapeutic use thereof
GB0602639D0 (en) Organic compounds
WO2009006267A3 (en) N'-(2-halobenzylidene)sulfonylhydrazides as intermediates in the manufacture of arylsulfonylindazoles
TW200740766A (en) Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6-ligands
SG152296A1 (en) Novel process for the preparation of 5-amino-3h-thiazolo[4,5-d]pyrimidin-2- one
WO2004067093A3 (en) Nk1 receptor antagonists for the treatment of functional dyspepsia

Legal Events

Date Code Title Description
FG Grant or registration